RWQ Financial Management Services Inc. Acquires 31,510 Shares of AbbVie Inc. $ABBV

Key Points

• RWQ Financial Management Services increased its AbbVie stake by 135.9%, purchasing 31,510 additional shares to hold 54,700 shares worth approximately $13.8 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• AbbVie exceeded quarterly expectations with $3.65 in adjusted EPS and $16.99 billion in revenue, up 10.2% year over year. The company also pays a $1.73 quarterly dividend, equivalent to a 2.8% annual yield.
• Analysts maintain a generally positive outlook, with AbbVie rated “Moderate Buy” and an average price target of $275.50 versus its recent $249.20 price. Growth catalysts include neuroscience and post-Humira product diversification, while elevated valuation and pipeline setbacks remain risks.

RWQ Financial Management Services Inc. increased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 135.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,700 shares of the company's stock after purchasing an additional 31,510 shares during the quarter. AbbVie accounts for 6.6% of RWQ Financial Management Services Inc.'s holdings, making the stock its 5th biggest position. RWQ Financial Management Services Inc.'s holdings in AbbVie were worth $13,765,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in AbbVie by 5.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 495,003 shares of the company's stock worth $124,563,000 after buying an additional 27,237 shares in the last quarter. Hidden Cove Wealth Management LLC increased its holdings in shares of AbbVie by 16.5% in the second quarter. Hidden Cove Wealth Management LLC now owns 2,600 shares of the company's stock valued at $654,000 after buying an additional 369 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of AbbVie by 368.4% in the second quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,288 shares of the company's stock valued at $324,000 after buying an additional 1,013 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of AbbVie by 1.1% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 324,551 shares of the company's stock valued at $81,670,000 after buying an additional 3,394 shares in the last quarter. Finally, MFA Wealth Services lifted its position in shares of AbbVie by 11.8% during the 2nd quarter. MFA Wealth Services now owns 3,401 shares of the company's stock valued at $856,000 after acquiring an additional 358 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

ABBV opened at $249.20 on Friday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The business has a 50-day moving average of $244.94 and a 200-day moving average of $226.12. The company has a market capitalization of $440.29 billion, a PE ratio of 70.40, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie's payout ratio is currently 195.48%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ABBV shares. Evercore set a $235.00 price objective on AbbVie in a research note on Friday, May 15th. BMO Capital Markets upped their target price on AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research report on Tuesday, June 23rd. HSBC reissued a "buy" rating and issued a $300.00 price target on shares of AbbVie in a research note on Monday, July 6th. Finally, Wolfe Research upgraded AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective on the stock in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and an average target price of $275.50.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source